BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineHematology & OncologyPulmonologyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerCancerUterine CancerGeneral HealthPrescription Drugs
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, April 2, 2019 (HealthDay News) -- For patients with advanced small cell lung cancer (SCLC), pembrolizumab shows antitumor activity with durable responses, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 29 to April 3 in Atlanta.
Hyun Cheol Chung, M.D., Ph.D., from the Yonsei Cancer Center in Seoul, South Korea, and colleagues presented outcomes for patients with confirmed incurable advanced SCLC enrolled in KEYNOTE-028 and KEYNOTE-158 who were receiving pembrolizumab after two or more lines of prior therapy. Pembrolizumab was administered for two years or until disease progression or intolerable toxicity. In both studies, the primary end point was objective response rate (ORR).
The researchers found that 83 of the 131 patients were eligible for efficacy analyses. The ORR was 19.3 percent. Two and 14 patients had a complete response and a partial response, respectively, per independent central review; of the responders, 14 were programmed death ligand 1-positive. The median duration of response was not reached. Sixty-one percent of the responders had a response lasting 18 months or more. Median progression-free survival (PFS) and median overall survival (OS) were 2.0 and 7.7 months, respectively. The 12-month rates for PFS and OS were 16.9 and 34 percent, respectively; the 24-month rates were 13.1 and 21 percent, respectively.
"Our study shows that pembrolizumab monotherapy can provide durable clinical benefit with manageable toxicity in this hard-to-treat patient population," Chung said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including Merck, which manufactures pembrolizumab and funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 27, 2022
Read this Next
Other Trending Articles